Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)-Reference-Cited by-同舟云学术

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Published:2023-05-04 Issue:6 Volume:37 Page:1175-1185
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Terpos Evangelos^ORCID,Musto Pellegrino^ORCID,Engelhardt Monika^ORCID,Delforge Michel,Cook Gordon^ORCID,Gay Francesca^ORCID,van de Donk Niels W. C. J.,Ntanasis-Stathopoulos Ioannis^ORCID,Vangsted Annette Juul^ORCID,Driessen Christoph,Schjesvold Fredrik^ORCID,Cerchione Claudio^ORCID,Zweegman Sonja,Hajek Roman^ORCID,Moreau Philippe^ORCID,Einsele Hermann^ORCID,San-Miguel Jesus^ORCID,Boccadoro Mario^ORCID,Dimopoulos Meletios A.^ORCID,Sonneveld Pieter^ORCID,Ludwig Heinz^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01920-1.pdf

Reference151 articles.

1. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13.

2. Sorrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed multiple myeloma patients: a Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102:182–90.

3. Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143–61.

4. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, et al. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023;98:49–55.

5. Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97:925–44.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA;American Journal of Hematology;2024-01-31

2. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation;Blood Advances;2023-12-29

3. Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders;Blood Advances;2023-11-03

4. Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab;Cancer Science;2023-10-26

5. Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis;Frontiers in Medicine;2023-10-09